Not Yet Recruiting NA NCT05925166

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

Safety and Efficacy of Of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein In Acute Gout

Sponsor: Lihua Duan

Interventions Triamcinolone Acetonide rhTNFR-Fc

Updated 4 times since 2023 Last updated: Jul 20, 2023 Started: Sep 1, 2023 Primary completion: Jul 1, 2026 Completion: Dec 31, 2026

A NA clinical study on Acute Gout, this trial is actively recruiting participants. The trial is conducted by Lihua Duan and has accumulated 4 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting NA
Aug 2023 — Jul 2024 [monthly]

Not Yet Recruiting NA
Jul 2023 — Aug 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lihua Duan

Data source: Jiangxi Provincial People's Hopital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanchang, China